Volume 2 Supplement 2

Abstracts from the 1st Immunotherapy of Cancer Conference (ITOC1)

Open Access

P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)

  • HM Specht1,
  • J Pelzel1,
  • H Hautmann2,
  • RM Huber3,
  • B Schossow4,
  • M Molls1 and
  • G Multhoff1
Journal for ImmunoTherapy of Cancer20142(Suppl 2):P41

https://doi.org/10.1186/2051-1426-2-S2-P41

Published: 12 March 2014

Membrane-bound Hsp70 serves as a recognition structure for NK cells that were pre-stimulated with Hsp70 peptide TKD plus low dose IL-2 in vitro and in mouse models. In a clinical phase I trial feasibility, safety and tolerability of ex vivo TKD/IL-2 stimulated autologous NK cells has been demonstrated in patients with metastasised colorectal carcinoma and NSCLC. Based on these findings a proof-of-concept phase II randomised clinical trial was initiated (BMBF - Innovative therapies). NSCLC patients will be treated with ex vivo stimulated NK cells after RCT. Most patients are diagnosed in locally advanced disease stages IIIA and IIIIB. After conventional radiochemotherapy only part of the patients (less than 50%) show remission and despite improvements in standard therapies the mortality associated with this disease is very high (5 year survival rate does not exceed 15%). Therefore there is a strong medical need for innovative treatment strategies. Since an Hsp70 membrane-positive tumour phenotype is associated with a poor clinical outcome, only Hsp70 membrane-positive tumour patients are recruited into the trial. Leukapharesis products are generated centralised and cell processing is performed in a GMP-laboratory.

The aim of the study is to show the efficacy of the treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard RCT by improvement of PFS.

Authors’ Affiliations

(1)
Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar - Technische Universität München
(2)
I.Medizinische Klinik - Pneumologie, Klinikum rechts der Isar - Technische Universität München
(3)
Medizinische Klinik - Innenstadt - Pneumologie, Ludwig-Maximilians-Universität
(4)
MSZ - Münchner Studien Zentrum, Klinikum rechts der Isar - Technische Universität München

Copyright

© Specht et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement